NRIX vs V · rev $54.5M vs P/E 33, rev $40.00B
Nurix Therapeutics Inc (NRIX) versus Visa Inc. Class A (V) — a side-by-side from cached financials, not a winner call.
Nurix Therapeutics Inc (NRIX) is a biotechnology company listed on NASDAQ.
Visa Inc. Class A (V) is a credit services company listed on US. It is led by Ryan McInerney.
Latest reported NRIX revenue for 2024-11-30 was $54.5M. Net income was -$193.6M. Revenue was down 29.1% from 2023-11-30 to 2024-11-30. NRIX currently screens at market cap $1.77B.
Latest reported V revenue for 2025-09-30 was $40.00B. Net income was $20.06B. V currently screens at market cap $659.78B and trailing P/E 33.5.
NRIX currently screens at market cap $1.77B. V currently screens at market cap $659.78B and trailing P/E 33.5.
Not investment advice. Open the NRIX and V stock pages for the full models.
Not investment advice.